Salivary gland dysfunction: A review of systemic therapies

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics

Volumn 92, Issue 2, 2001, Pages 156-162

  Grisius, Margaret M ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIINFLAMMATORY AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; MUSCARINIC AGENT;

ALTERNATIVE MEDICINE; ANIMAL; CONTROLLED CLINICAL TRIAL; DENTAL CARIES; DRUG EFFECT; DYSPHAGIA; HUMAN; MICROBIOLOGY; MOUTH DISEASE; PATHOPHYSIOLOGY; REVIEW; SALIVARY GLAND; SALIVATION; XEROSTOMIA;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHOLINERGIC AGONISTS; COMPLEMENTARY THERAPIES; CONTROLLED CLINICAL TRIALS; DEGLUTITION DISORDERS; DENTAL CARIES; HUMANS; INTERFERON-ALPHA; MOUTH DISEASES; MUSCARINIC AGONISTS; PARASYMPATHOMIMETICS; SALIVARY GLANDS; SALIVATION; XEROSTOMIA;

EID: 0035430979     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1067/moe.2001.116601     Document Type: Article

References (54)

1. Baum BJ. Neurotransmitter control of secretion. J Dent Res 1987;Special Issue:628-32.
2. Doods HN, Mathy MJ, Davidesko D, van Charldorp KJ, de Jonge A, van Zwieten PA. Selectivity of muscarinic antagonists in radioligand and in vivo experiments for the putative M1, M2 and M3 receptors. J Pharmacol Exp Ther 1987;242:257-62.
3. Iwabuchi Y, Masuhara T. Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjögren's syndrome. Gen Pharmac 1994;25:123-9.
4. Fox PC, van der Yen PF, Baum BJ, Mandel ID. Pilocarpine for the treatment of xerostomia associated with salivary gland dysfunction. Oral Surg Oral Med Oral Pathol 1986;61:243-8.
5. Valdez IH, Wolff A, Atkinson JC, Macynski AA, Fox PC. Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction. Cancer 1993;71:1848-52.
6. Johnson JT, Ferretti GA, Nethery WJ, Valdez IH, Fox PC, Ng D, et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 1993;329:390-5.
7. Vivino FB, Al-Hashimi I, Khan Z, LeVeque FG, Saliasbury PL III, Tran-Johnson TK, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. Arch Intern Med 1999;159:174-81.
8. Fox PC, Atkinson JC, Macynski AA, Wolff A, Kung DS, Valdez IH, et al. Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia). Arch Intern Med 1991;151:1149-52.
9. LeVeque FG, Montgomery M, Potter D, Zimmer MB, Rieke JW, Steiger BW, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol Jun 1993;11:1124-31.
10. Physician's Desk Reference 2001. Pilocarpine. Montvale (NJ): Medical Economics Company, Inc.
11. Iwabuchi Y, Katagiri M, Masuhara T. Salivary secretion and histopathological effects after single administration of the muscarinic agonist SNI-2011 in MRL/lpr mice. Arch Int Pharmacodyn Ther 1994;328:315-25.
12. Iwabuchi Y, Masuhara T. Sialogogic activities of SNI-2001 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjögren's syndrome. Gen Pharmac 1994;25: 123-9.
13. Ninomiya T, Iga Y, Fukui K, Arisawa H, Uomatsu Y, Masunaga H, et al. The pharmacological profile of cevimeline (SNI-2011)/ A novel muscarinic agonist for the treatment of xerostomia in various models. Arthritis Rheum 1998;41:5329.
14. Fox RI, Petrone D, Condemi J, Fife R, Delgin P. Randomized placebo controlled trial of SNI-2011, A novel M3 muscarinic receptor agonist for the treatment of Sjögren's syndrome. Arthritis Rheum 1998;41:580.
15. Physician's Desk Reference 2001. Cevimeline. Montvale (NJ): Medical Economics Company, Inc.
16. Everett HC. The use of bethanechol chloride with tricyclic antidepressants. Am J Psychiatry 1975;132:1202-4.
17. Schubert DS. The use of bethanechol chloride with phenothiazines: a case report. Am J Psychiatry 1979;136:110-1.
18. Physician's Desk Reference 2001. Bethanechol. Montvale (NJ): Medical Economics Company Inc.
19. Epstein JB, Decoteau WE, Wilkinson A. Effect of Sialor in treatment of xerostomia in Sjögren's syndrome. Oral Surg Oral Med Oral Pathol 1983;56:495-9.
20. Schiødt M, Oxholm P, Jacobsen A. Sulfarlem S25 in the treatment of primary Sjögren's syndrome. Scand J Rheumatol 1986; 61:250-2.
21. Lelard G, Mercat C, Fuseiller C. Action favourable du trithioparamethoxyphenylpropene sur le complications salivaries des traitments psychotrope. Rev Med Tours 1969;3:343-4.
22. DeBuck R, Titeca R, Pelc I. Etude controlee de l'action de l' Anetholtrithione sur les asialies et leshyposialies provoquees par les medicaments psychotropices. 1973;73:510-9.
23. Malmström MJ, Segerberg-Konttinen M, Tuominen TS, Hietanen JH, Wolf JE, Sane JI, et al. Xerostomia due to Sjögren's syndrome. Diagnostic criteria, treatment and outlines for a continuous dental care programme and an open trial with Sulfarlem. Scand J Rheumatol 1988;17:77-86.
24. Hamada T, Nakane T, Kimura T, Arisawa K, Yoneda K, Yamamoto T, et al. Treatment of xerostomia with the bile secretion stimulating drug anethole-trithione: A clinical trial. Am J Med Sci 1999;318:3:146-51.
25. Frost-Larsen K, Isager H, Manthorpe R. Sjögren's syndrome treated with bromhexine: a randomized clinical study. Br Med J 1978;i:1579-81.
26. Manthorpe R, Frost-Larsen K, Hoj L, Isager H, Prause JV. Bromhexine treatment of Sjögren's syndrome: effect on lacrimal and salivary secretion and on proteins in tear fluid and saliva. Scand J Rheumatol 1981;10:177-80.
27. Prause JV, Frost-Larsen K, Hoj L, Isager H, Manthorpe R. Lacrimal and salivary secretion in Sjögren's syndrome: The effect of systemic treatment with bromhexine. Acta Ophthalmol 1984;62:489-97.
28. Tapper-Jones LM, Aldred MJ, Cadogan SJ, Walker DM, Dolby AE, Hopkins R, et al. Sjögren's syndrome treated with bromhexine: a reassessment. Br Med J 1980;i:1356.
29. Nahir AM, Ben Aryeh H, Szargel R, Sharf Y, Gutman D, Blausten Y, et al. Sialochemistry in evaluating bromhexine treatment of Sjögren's syndrome. Br Med J 1979;ii:833.
30. Avisar R, Savir H, Machtey I, Ovakin L, Shaked P, Menache R, et al. Clinical trial of bromhexine in Sjögren's syndrome. Ann Ophthalmol 1981;13:971-3.
31. Grisius MM, Bermudez DK, Fox PC. Salivary and serum interleukin 6 in primary Sjögren's syndrome. J Rheumatol 1997; 24:1089-91.
32. Shiozawa S, Morimoto I, Tanaka Y, Shiozawa K. A preliminary study of the interferon-alpha treatment for xerostomia of Sjögren's syndrome. Br J Rheumatol 1993;32:52-4.
33. Ferraccioli GF, Salaffi F, De Vita S, Casatta I, Avellini C, Carotti M, et al. Interferon alpha-2 (IFN alpha 2) increases lacrimal and salivary function in Sjögren's syndrome patients. Preliminary results of an open pilot trial versus OH-chloroquine. Clin Exp Rheumatol 1996;14:367-71.
34. Shiozawa S, Tanaka Y, Shiozawa K. Single-blinded controlled trial of low dose oral IFN-alpha for the treatment of Sjögren's syndrome. J Interferon Cytokine Res 1998;18:255-62.
35. Kohler PF, Winter ME. A quantitative test for xerostomia. The Saxton test. Arthritis Rheum 1985;28:1128-32.
36. Ship JA, Fox PC, Michalek JE, Cummins MJ, Richards AB. Treatment of primary Sjögren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN protocol study group. J Interferon Cytokine Res 1999;19:943-51.
37. Kruize AA, Hene RJ, Kallenberg CG, van Bijsterveld OP, van der Heide A, Kater L, et al. Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. Ann Rheum Dis 1993;52:360-4.
38. Fox RI, Dixon R, Guarassi V, Krubel S. Treatment of primary Sjögren's syndrome hydroxychloroquine: a retrospective, open-label study. Lupus 1996;Suppl 1:831-6.
39. Manoussakis MN, Moutsopoulos HM. Antimalarials in Sjögren's syndrome - the Greek experience. Lupus 1996;Suppl 1:S28-30.
40. Fox PC, Datiles M, Atkinson JC, Macynski AA, Scott J, Valdez IH, et al. Prednisone and piroxicam for treatment of primary Sjögren's syndrome. Clin Exp Rheumatol 1993;11:149-56.
41. Skopouli FN, Jagiello P, Tsifetaki N, Moutsopoulos HM. Methotrexate in primary Sjögren's syndrome. Clin Exp Rheumatol 1996;14:555-8.
42. Bagheri H, Schmitt L, Berlan M, Montastruc JL. A comparative study of the effects of yohimbine and anetholtrithione on salivary secretion in depressed patients treated with psychotropic drugs. Eur J Clin Pharmacol 1997;52;5:339-42.
43. Pedersen A, Gerner N, Palmvang I, Hoier-Madsen M. LongoVital in the treatment of Sjögren's syndrome. Clin Exp Rheumatol 1999; 5:533-8.
44. Kempe C, Gruning H, Stasche N, Hermann K. [Icelandic moss lozenges in the prevention or treatment of oral mucosa irritation and dried out throat]. Laryngo Rhino Otologie 1997;3: 186-8.
45. Ohno S, Suzuki T, Dohi Y. [The effect of bakumondo-to on salivary secretion in Sjögren's syndrome]. Ryumachi 1990;30;1:10-6.
46. Kagami H, Horie K, Nishiguchi H, Shigetomi T, Ueda M. Effect of bakumondo-to, a Chinese-Japanese herbal medicine, on cultures and dispersed salivary gland cells. J Ethnopharmacol 1996; 2:89-95.
47. Blom M, Lundeberg T, Dawidson I, Angmar-Mansson. Effects on local blood flux of acupuncture stimulation used to treat xerostomia in patients suffering from Sjögren's syndrome. J Oral Rehab 1993;5:541-8.
48. Dawidson I, Angmar-mansson B, Blom M, Theodorsson E, Lundeberg T. Sensory stimulation (acupuncture) increases the release of vasoactive intestinal polypeptide in the saliva of xerostomia suffers. Neuropeptides 1998;32;6:543-8.
49. Blom M, Dawidson I, Angmar-Mansson B. Acupuncture treatment of xerostomia caused by irradiation of head and neck region: case reports. J Oral Rehab 1993;20;5:491-4.
50. Dawidson I, Blom M, Lundeberg T, Angmar-Mansson B. The influence of acupuncture on salivary flow rates in healthy subjects. J Oral Rehab 1997;24;3:204-8.
51. Pal B. Use of alternative medicine by Sjögren's syndrome patients. Clinical Exp Rheumatol 1998;16;6:763.
52. Zheighe Z, Jianmin Z. [The experimental observations on the changes of salivary IgA and lysozyme before and after Qigong practicing]. Qigong 1982;3:3.
53. Gong B. [GiGong and salivary secretion]. Qigong 1080;1;1:19.
54. Blom M, Kopp S, Lundeberg T. Prognostic value of the pilocarpine test to identify patients who may obtain long-term relief from xerostomia by acupuncture treatment. Arch Otolaryngol Head Neck Surg 1999;125:561-6.